PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of gutGutCurrent TOCInstructions to authors
 
Gut. Jul 2007; 56(7): 898–900.
PMCID: PMC1994372

Helicobacter bilis: bacterial provocateur orchestrates host immune responses to commensal flora in a model of inflammatory bowel disease

Short abstract

Helicobacter bilis can elicit heterologous immune responses to lower gut flora

The gastrointestinal tracts of mammals, including mice, are colonised with a diverse microecosystem. The caeca of normal conventional mice have been estimated to contain from 100 to 1000 individual species, and the number of bacteria can reach levels of up to 1011 bacteria/g of faeces.1,2 These microorganisms provide essential nutrients for their host and also colonise mucosal niches, which may partly influence the host response against microbial pathogens.2,3,4,5,6,7 By far, the greatest concentration and different types of bacteria comprising the gastrointestinal microflora of mice and humans reside in the caecum and colon.8,9,10 The fusiform‐shaped bacteria, spirochetes and spiral‐shaped bacteria were shown by histology to be almost exclusively located in the mucinous secretion overlaying the epithelium of the large bowel, and apparently in intimate association with the epithelial barrier.10 In the 1960s, Schaedler et al11 colonised germ‐free mice with selected bacteria isolated from “normal” mice. He then supplied animal breeders with this series of microorganisms12,13 for use in colonising their mouse colonies. The one known as the Schaedler flora (SF) was the most popular. It contained eight anaerobic bacteria. In 1978, National Cancer Institute revised the SF of eight anaerobic bacteria to standardise the microbiota to be used in colonising axenic (germ‐free) rodents. The newly defined microbiota, now known as altered Schaedler flora (ASF), consisted of two lactobacilli, a Bacteroides sp, a spiral‐shaped bacterium and four fusiform‐shaped, extremely oxygen‐sensitive bacteria.14

In the past, monitoring of the gnotobiotic animals relied on examining the morphology of the microorganisms with a limited evaluation of the organisms, biochemical traits and growth characteristics. Most published mouse studies evaluating the pathogenesis of inflammatory bowel disease (IBD) therefore simply refer to gut flora as conventional or specific pathogen‐free (SPF) flora. Because of the limitations of the monitoring system used to identify the bacteria in ASF, as well as little or no characterisation of the flora in IBD mouse models, we recently characterised the phylogenetic positions of the ASF relative to known bacteria by using 16S rRNA sequence analysis15 and ascertained their distribution in the mouse gut using quantitative PCR.16 Importantly, this modified ASF is still being used by commercial breeders when establishing the gastrointestinal flora for their barrier‐maintained SPF mice.

Although no animal model faithfully recapitulates all the features of IBD, rodent models that reproduce important hallmarks of the human disease are used extensively to investigate basic pathogenetic components of Crohn's disease and ulcerative colitis. Studies of the roles of endogenous microflora in IBD‐like disease in mice are complicated by the fact that results depend on the management practices where the in vivo experiments are conducted. Under “conventional housing conditions”, genetically engineered mice, particularly those with immune dysregulation, develop typhlocolitis when maintained in some facilities, but remain free of disease in others. The importance of the gastrointestinal flora is highlighted by the fact that germ‐free mice, with this permissive IBD phenotype, do not develop IBD. More recently, investigators are using the newly identified murine pathogens, Helicobacter hepaticus and H bilis to elicit IBD in these models.17,18H hepaticus and H bilis are endemic in most academic mouse colonies and have reliably induced disease in susceptible mouse strains in virtually all non‐germ‐free environments.19,20,21,22,23,24

Jergens et al25 (see page 934) present interesting data using a variation of this model, which supports a role for H bilis infection in eliciting typhlocolitis in defined ASF C3H/HeN mice, as well as an unanticipated finding that mice infected with H bilis also develop an immune response to the commensal ASF, a response not observed in control mice nor in mice treated with dextran sodium sulphate (DSS).25 This model of IBD is intriguing and potentially very useful, given this inbred strain is an immunocompetent host, unlike the majority of IBD mouse models that have varying degrees of immune dysregulation. In their study, in addition to histological evaluation of intestinal tissues, the IgG1 (T helper cell 2 (Th2)) and IgG2a (Th1) serological immune responses to H bilis and ASF in mice were measured using ELISA. Cytokine assessment of unfractionated single‐cell suspensions of spleen and mesenteric lymph node (MLN) stimulated with concanavalin A (ConA) was conducted. ASF and H bilis antigens were used to evaluate overall T cell responses.

Examination of the data indicated a robust IgG response to H bilis in association with significant increases in cytokine responses, and revealed that the C3H/HeN strain had a balanced immune response to the helicobacter infection. Notably, both Th1‐ and Th2‐associated cytokine responses to in vitro stimulation with H bilis antigen were apparent. This is also reflected in histology data that demonstrated a mild to moderate inflammatory response one that is not so severe as to debilitate the host. The chronic inflammatory response to H bilis that developed over a 10‐week period may also explain why an immune response to ASF antigens was not observed in the acute DSS model.

The authors also measured antibody responses to each of the eight ASF species; however, they chose to present data as a mean of the composite antibody response for statistical comparisons. In aggregate, H bilis‐infected mice had statistically higher IgG levels (both Th1 and Th2) to ASF than controls. Although the data were not shown in detail, the authors stated that H bilis‐infected mice had higher overall IgG responses to four of the ASF (ASF 457, Mucospirillum schaedleri; ASF 500, low‐content G+C‐positive bacteria; ASF 502, Clostridium spp; and ASF 519, Bacteroides distasonis) than the other four ASF, two of which are Lactobacillus spp. C3H/HeJ Bir mice, which are reported to develop spontaneous colitis, also develop selective antibody reactivity to caecal bacterial antigens26; these antibodies were composed primarily of IgG2a and, to a lesser extent, IgG1. However, unlike Jergen's findings, antibody reactivity was predominantly to antigens of aerobic and not to those of anaerobic bacteria. Interestingly, after rederivation of the C3H/HeJ Bir mice, likely to have been infected with enteric helicobacters and housed in SPF facilities (without helicobacters), there was a marked reduction in intestinal lesions.26

The serological titre to M schaedleri may, in part, be explained by the ability of this organism to readily translocate across intestinal mucosa and colonise the liver of both conventional and mono‐associated germ‐free mice.27,28 Whether the other three ASF‐evoking systemic immune responses in the C3H/HeN mouse model have similar invasive properties is not known.7 Alternatively, H bilis‐infected mice may have activated dendritic cells that are more capable of processing luminal enteric bacterial antigens and/or may respond to antigens shared by H bilis and select species of ASF.29 It is tempting to speculate that lower antibody responses to lactobacilli, which may have probiotic anti‐inflammatory activity, was reflected in H bilis‐infected mice that had only mild to moderate bowel inflammation and increased, but balanced, cytokine responses (interferon γ (IFNγ), tumour necrosis factor α (TNFα), interleukin 6 (IL6), IL10 and IL12) in splenocyte preparations.30 It is important to determine whether the typhlocolitis observed in this model persists 10 weeks after H bilis infection, the time point at which this study was concluded. If H bilis had truly induced an ongoing lower bowel inflammatory response to ASF antigens, one would expect ongoing, chronic colitis. Alternatively, the host immune response may change the colonisation dynamics between H bilis and ASF as well as between individual species of ASF as reported previously.31,32 Future experiments are probably being planned by the authors to ascertain whether H bilis perturbs the colonisation density or distribution of ASF in the intestinal tract in a manner similar to H hepaticus in SW mice or H trogontum infection in IL10−/− mice.31,32 These data may provide insight into the host's varying immune response to ASF after H bilis infection and may help explain why serological IgG responses and inflammatory tissue responses (severity of lesion) decreased after an initial peak activity.

H bilis infection also has had an unanticipated impact on primary gastric helicobacter infection in mice. Previous studies in our laboratory demonstrated that concurrent helminth infection modulated inflammation and gastric immune responses and reduced helicobacter‐induced gastric atrophy.33 With this in mind, we recently investigated the ability of H bilis to modulate the pathogenesis of experimental H pylori infection in C57BL/6 mice. Interestingly, mice coinfected with H bilis and H pylori had significantly less gastric inflammation at both 6 and 11 months after infection compared with mice monoinfected with H pylori. Serological analysis of IgG2c and IgG1 titres to H pylori was predictive of gastritis scores at 6 and 11 months after infection, revealing significantly higher Th1‐associated H pylori‐specific IgG2c responses to H pylori in mice monoinfected with H pylori than in mice coinfected with H pylori and H bilis. Cytokine analysis also indicated that H pylori‐monoinfected mice had significantly increased levels of IFNγ and TNFα at both 6 and 11 months after infection, and significantly increased IL1β and the aforementioned cytokines at 11 months when compared with mice coinfected with H pylori and H bilis and control mice. These data suggest that concurrent infection with H bilis can ameliorate gastric helicobacter pathology with concommitant attenuation of H pylori Th1‐mediated gastric and systemic immune responses.34 Clearly, further studies are needed to determine the mechanisms for the protective effects of apparent heterologous immunity to H bilis against helicobacter‐associated gastric disease and to understand how H bilis can elicit a heterologous immune response to lower gut flora, and whether, as Jergen et al suggest, this immune response to normal ASF flora plays a role in the initiation and progression of IBD. In this context, patients with Crohn's disease have immune responses to intestinal microflora.35,36 These provocative findings suggest that it is no longer sufficient to ascribe the initiation, progression or attenuation of gastrointestinal disease simply to the presence of undefined indigeneous flora eliciting chronic inflammation after the loss of immune tolerance. Whether humans with IBD have key provocateur bacterial species orchestrating the host's response to the gastrointestinal microflora and the development or attenuation of chronic gastrointestinal disease remains an unsolved and largely unexplored hypothesis.

Footnotes

Competing interests: None.

References

1. Xu J, Gordon J I. Inaugural article: honor thy symbionts. Proc Natl Acad Sci USA 2003. 10010452–10459.10459. [PubMed]
2. Schaedler R W, Orcutt R P. Gastrointestinal microflora. In: Foster HL, Small JD, Fox JG, eds. The mouse in biomedical research, III. New York: Academic Press, 1983. 327–345.345.
3. Eckburg P B, Bik E M, Bernstein C N. et al Diversity of the human intestinal microbial flora. Science 2005. 3081635–1638.1638. [PMC free article] [PubMed]
4. Singer S M, Nash T E. The role of normal flora in Giardia lamblia infections in mice. J Infect Dis 2000. 1811510–1512.1512. [PubMed]
5. Steffen E K, Berg R D. Relationship between cecal population levels of indigenous bacteria and translocation to the mesenteric lymph nodes. Infect Immun 1983. 391252–1259.1259. [PMC free article] [PubMed]
6. Thompson G E. Control of intestinal flora in animals and humans: implications for toxicology and health. J Environ Pathol Toxicol 1978. 1113–123.123. [PubMed]
7. Wells C L, Maddaus M A, Reynolds C M. et al Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 1987. 552689–2694.2694. [PMC free article] [PubMed]
8. Savage D C, McAllister J S, Davis C P. Anaerobic bacteria on the mucosal epithelium of the murine large bowel. Infect Immun 1971. 4492–502.502. [PMC free article] [PubMed]
9. Gill S R, Pop M, Deboy R T. et al Metagenomic analysis of the human distal gut microbiome. Science 2006. 3121355–1359.1359. [PubMed]
10. Savage D C, Dubos R, Schaedler R W. The gastrointestinal epithelium and its autochthonous bacterial flora. J Exp Med 1968. 12767–76.76. [PMC free article] [PubMed]
11. Schaedler R W, Dubos R, Costello R. Association of germfree mice with bacteria isolated from normal mice. J Exp Med 1965. 12277–82.82. [PMC free article] [PubMed]
12. Baker D E. The commercial production of mice with a specified flora. Natl Cancer Inst Monogr 1966. 20161–166.166. [PubMed]
13. Gordon H A, Pesti L. The gnotobiotic animal as a tool in the study of host microbial relationships. Bacteriol Rev 1971. 35390–429.429. [PMC free article] [PubMed]
14. Orcutt R P, Gianni F, Judge R. Development of an “altered Schaedler flora” for NCI gnotobiotic rodents. Microecol Ther 1987. 1759.
15. Dewhirst F E, Chien C C, Paster B J. et al Phylogeny of the defined murine microbiota: altered Schaedler flora. Appl Environ Microbiol 1999. 653287–3292.3292. [PMC free article] [PubMed]
16. Sarma‐Rupavtarm R B, Ge Z, Schauer D B. et al Spatial distribution and stability of the eight microbial species of the altered Schaedler flora in the mouse gastrointestinal tract. Appl Environ Microbiol 2004. 702791–2800.2800. [PMC free article] [PubMed]
17. Fox J G, Dewhirst F E, Tully J G. et al Helicobacter hepaticus sp. nov., a microaerophilic bacterium isolated from livers and intestinal mucosal scrapings from mice. J Clin Microbiol 1994. 321238–1245.1245. [PMC free article] [PubMed]
18. Fox J G, Yan L L, Dewhirst F E. et al Helicobacter bilis sp. nov., a novel Helicobacter species isolated from bile, livers, and intestines of aged, inbred mice. J Clin Microbiol 1995. 33445–454.454. [PMC free article] [PubMed]
19. Cahill R J, Foltz C J, Fox J G. et al Inflammatory bowel disease: an immunity‐mediated condition triggered by bacterial infection with Helicobacter hepaticus. Infect Immun 1997. 653126–3131.3131. [PMC free article] [PubMed]
20. Chin E Y, Dangler C A, Fox J G. et al Helicobacter hepaticus infection triggers inflammatory bowel disease in T cell receptor alphabeta mutant mice. Comp Med 2000. 50586–594.594. [PubMed]
21. Fox J G, Yan L, Shames B. et al Persistent hepatitis and enterocolitis in germfree mice infected with Helicobacter hepaticus. Infect Immun 1996. 643673–3681.3681. [PMC free article] [PubMed]
22. Shomer N H, Dangler C A, Schrenzel M D. et al Helicobacter bilis‐induced inflammatory bowel disease in SCID mice with defined flora. Infect Immun 1997. 654858–4864.4864. [PMC free article] [PubMed]
23. Jiang H Q, Kushnir N, Thurnheer M C. et al Monoassociation of SCID mice with Helicobacter muridarum, but not four other enterics, provokes IBD upon receipt of T cells. Gastroenterology 2002. 1221346–1354.1354. [PubMed]
24. Rogers A B, Fox J G. Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am J Physiol Gastrointest Liver Physiol 2004. 286G361–G366.G366. [PubMed]
25. Jergens A E, Wilson‐Welder J, Dorn A. et al Helicobacter bilis triggers persistent immune reactivity to antigens derived from the commensal bacteria in gnotobiotic C3H/HeN mice. Gut 2007. 56934–940.940. [PMC free article] [PubMed]
26. Brandwein S L, McCabe R P, Cong Y. et al Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997. 15944–52.52. [PubMed]
27. Robertson B R, O'Rourke J L, Neilan B A. et al Mucispirillum schaedleri gen. nov., sp. nov., a spiral‐shaped bacterium colonizing the mucus layer of the gastrointestinal tract of laboratory rodents. Int J Syst Evol Microbiol 2005. 551199–1204.1204. [PubMed]
28. Kirchain S, Taylor N, Whary M. et al Colonization of germ‐free mice with Mucispirillum schaedleri, a spiral bacterium of the rodent intestinal tract. J Am Assoc Lab Anim Sci2006. 45128.
29. Niess J H, Brand S, Gu X. et al CX3CR1‐mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science 2005. 307254–258.258. [PubMed]
30. Pena J A, Rogers A B, Ge Z. et al Probiotic Lactobacillus spp. diminish Helicobacter hepaticus‐induced inflammatory bowel disease in interleukin‐10‐deficient mice. Infect Immun 2005. 73912–920.920. [PMC free article] [PubMed]
31. Ge Z, Feng Y, Whary M T. et al Cytolethal distending toxin is essential for Helicobacter hepaticus colonization in outbred Swiss Webster mice. Infect Immun 2005. 733559–3567.3567. [PMC free article] [PubMed]
32. Whary M T, Danon S J, Feng Y. et al Rapid onset of ulcerative typhlocolitis in B6.129P2‐IL10tm1Cgn (IL‐10‐/‐) mice infected with Helicobacter trogontum is associated with decreased colonization by altered Schaedler's flora. Infect Immun 2006. 746615–6623.6623. [PMC free article] [PubMed]
33. Fox J G, Beck P, Dangler C A. et al Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces helicobacter‐induced gastric atrophy. Nat Med 2000. 6536–542.542. [PubMed]
34. Lemke L, Whary M, Ge Z. et al Concurrent Helicobacter bilis infection in C57BL/6 mice modulates systemic and gastric immune responses and attenuates gastric pathology associated with H pylori infection. 2007. Abstract DDW Washington, DC.
35. Pirzer U, Schonhaar A, Fleischer B. et al Reactivity of infiltrating T lymphocytes with microbial antigens in Crohn's disease. Lancet 1991. 3381238–1239.1239. [PubMed]
36. Macpherson A, Khoo U Y, Forgacs I. et al Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 1996. 38365–375.375. [PMC free article] [PubMed]

Articles from Gut are provided here courtesy of BMJ Group